# DataMeds AI, Inc. (MEDS) · Edgar & Edgarette company card

> DataMeds AI (MEDS) grew revenue 28.7% in FY2025 to $23 million, operating margin -402% against a 1.4% median for drugs, proprietaries & druggists' sundries, equity -40.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 2030763 · fiscal year ended 2025-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/MEDS) · [JSON](https://www.pops4.com/boards/company/MEDS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $23M |
| Revenue growth, 1 year | 28.7% |
| Revenue growth per year | — |
| Operating margin | -401.7% (prior year -33.9%) |
| Net margin | -433.9% |
| Operating cash flow | −$11M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $42,571 |
| Long-term debt | $23M |
| Total assets | $30M |
| Total equity | −$12M |
| Equity ÷ assets | -40.9% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -38.68 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late quarterly report notice, auditor change in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -401.7% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $23.3M (FY2025), total debt $23.5M. Experience: revenue up 28.7% on the year; operating margin -401.7%, down from -33.9%. Soundness: equity -40.9% of assets (liabilities exceed assets). Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $22.0M and $39.6M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (30 filers, $50M+ revenue, its industry group): operating margin -401.7% against a 1.4% median; growth 28.7% against 0.9%.

Range logged 2026-09-20, receipt a5a55356f9b68712, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 3, latest 2026-10-16 ([filing](https://www.sec.gov/Archives/edgar/data/2030763/000149315226047451/0001493152-26-047451-index.htm))
- Item NT 10-Q Late quarterly report notice: 3, latest 2026-08-14 ([filing](https://www.sec.gov/Archives/edgar/data/2030763/000149315226038378/0001493152-26-038378-index.htm))
- Item 4.01 Auditor change: 1, latest 2025-11-17 ([filing](https://www.sec.gov/Archives/edgar/data/2030763/000149315225023918/0001493152-25-023918-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-05-21 ([filing](https://www.sec.gov/Archives/edgar/data/2030763/000149315226024723/0001493152-26-024723-index.htm))

## Recent filings

- 8-K · filed 2026-10-26 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2030763/000149315226048573/0001493152-26-048573-index.htm)
- 8-K · filed 2026-10-20 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2030763/000149315226047711/0001493152-26-047711-index.htm)
- 8-K · filed 2026-10-16 · 1.01 Entry into a Material Definitive Agreement; 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 3.02 Unregistered Sales of Equity Securities · [filing](https://www.sec.gov/Archives/edgar/data/2030763/000149315226047451/0001493152-26-047451-index.htm)
- 8-K · filed 2026-10-13 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/2030763/000149315226046887/0001493152-26-046887-index.htm)
- 8-K · filed 2026-09-17 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/2030763/000149315226043169/0001493152-26-043169-index.htm)
- 8-K · filed 2026-09-16 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2030763/000149315226042951/0001493152-26-042951-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0002030763.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2030763

## Cite

POPS4, Edgar & Edgarette: DataMeds AI, Inc. (MEDS) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/MEDS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.